Skip to content

Study · Animal study (in vivo) · 2016

8 results

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.

Yamazaki T, Pitt JM, Vétizou M, Marabelle A, Flores C, Rekdal Ø, Kroemer G, Zitvogel L

Cell death and differentiation15 Apr 2016Cited by 77 (Europe PMC)

PMID27082453 (opens in a new tab)PMCIDPMC4987735 (opens in a new tab)DOI10.1038/cdd.2016.35 (opens in a new tab)PepBankPUB-27082453
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In animal tumors, LTX‑315 decreased local immunosuppressive Treg abundance.

    In plain wordsIn animals, LTX‑315 decreased local immunosuppressive Treg cells in tumors.

    Peptide
    LTX-315
    Outcome
    DecreaseLocal Treg abundance
    Study

    n: not reported in source

    cancers
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here, we show that LTX-315 rapidly reprograms the tumor microenvironment by decreasing the local abundance of immunosuppressive Tregs and myeloid-derived suppressor cells and by increasing the frequency of polyfunctional T helper type 1/type 1 cytotoxic T cells
  2. 02AnimalAnimal study (in vivo)Mechanism

    In animal tumors, LTX‑315 decreased local myeloid-derived suppressor cell abundance.

    In plain wordsIn animals, LTX‑315 decreased local myeloid-derived suppressor cells in tumors.

    Peptide
    LTX-315
    Outcome
    DecreaseMyeloid-derived suppressor cell abundance
    Study

    n: not reported in source

    cancers
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here, we show that LTX-315 rapidly reprograms the tumor microenvironment by decreasing the local abundance of immunosuppressive Tregs and myeloid-derived suppressor cells and by increasing the frequency of polyfunctional T helper type 1/type 1 cytotoxic T cells
  3. 03AnimalAnimal study (in vivo)Mechanism

    In animal tumors, LTX‑315 increased polyfunctional T helper type 1/type 1 cytotoxic T-cell frequency.

    In plain wordsIn animals, LTX‑315 increased polyfunctional T helper and cytotoxic T-cell frequency in tumors.

    Peptide
    LTX-315
    Outcome
    IncreasePolyfunctional T-cell frequency
    Study

    n: not reported in source

    cancers
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here, we show that LTX-315 rapidly reprograms the tumor microenvironment by decreasing the local abundance of immunosuppressive Tregs and myeloid-derived suppressor cells and by increasing the frequency of polyfunctional T helper type 1/type 1 cytotoxic T cells
  4. 04AnimalAnimal study (in vivo)Mechanism

    In animal tumors, LTX‑315 increased CTLA4 expression.

    In plain wordsIn animals, LTX‑315 increased CTLA4 expression in tumors.

    Peptide
    LTX-315
    Outcome
    IncreaseCTLA4 expression
    Study

    n: not reported in source

    cancers
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with a concomitant increase in cytotoxic T-lymphocyte antigen-4 (CTLA4) and drop in PD-1 expression levels.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In animal tumors, LTX‑315 decreased PD-1 expression.

    In plain wordsIn animals, LTX‑315 decreased PD-1 expression in tumors.

    Peptide
    LTX-315
    Outcome
    DecreasePD-1 expression
    Study

    n: not reported in source

    cancers
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with a concomitant increase in cytotoxic T-lymphocyte antigen-4 (CTLA4) and drop in PD-1 expression levels.

Studies that did not test the peptide alone3

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

  1. 06AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome

    In animals with tumors resistant to CTLA4 blockade, subsequent local LTX‑315 cured animals or caused tumor regressions.

    In plain wordsIn animals with tumors resistant to CTLA4 blockade, subsequent local LTX‑315 cured animals or caused tumor regression.

    Peptide
    LTX-315
    Outcome
    DecreaseCure or tumor regression
    Study

    n: not reported in source

    cancers
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Logically, in tumors that were resistant to intratumoral or systemic CTLA4 blockade, subsequent local inoculation of LTX-315 cured the animals or caused tumor regressions with abscopal effects.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  2. 07AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome

    In animals with tumors resistant to CTLA4 blockade, subsequent local LTX‑315 caused tumor regressions with abscopal effects.

    In plain wordsIn animals with tumors resistant to CTLA4 blockade, subsequent local LTX‑315 caused tumor regression with effects at distant sites.

    Peptide
    LTX-315
    Outcome
    DecreaseAbscopal effects
    Study

    n: not reported in source

    cancers
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Logically, in tumors that were resistant to intratumoral or systemic CTLA4 blockade, subsequent local inoculation of LTX-315 cured the animals or caused tumor regressions with abscopal effects.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  3. 08AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism

    In animal tumors, CD122 blockade reduced synergy between CTLA4 blockade and LTX‑315.

    In plain wordsIn animals, CD122 blockade reduced synergy between CTLA4 blockade and LTX‑315.

    Peptide
    LTX-315
    Outcome
    DecreaseCD122-dependent synergy
    Study

    n: not reported in source

    cancers
    Comparator
    without CD122 blockade
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    This synergistic interaction between CTLA4 blockade and LTX-315 was reduced upon blockade of the β-chain of the interleukin-2 receptor (CD122).

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.